Tweet
Ann Pharmacother. 2011 Nov 24. [Epub ahead of print]
Pharmacokinetic Assessment of Peramivir in a Hospitalized Adult Undergoing Continuous Venovenous Hemofiltration (December).
Scheetz MH, Griffith MM, Ghossein C, Hollister AS, Ison MG.
Source
< Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL.
Abstract
OBJECTIVE:
To report a sieving coefficient for peramivir in a patient receiving continuous venovenous hemofiltration (CVVH).
CASE SUMMARY:
An 18-year-old male presented with chills, myalgias, and dyspnea and was hospitalized. Nasal secretions were positive for influenza by rapid antigen test at an outside facility and oseltamivir was commenced. Oral absorption was predicted to be unreliable, and intravenous peramivir was accessed as an emergency investigational new drug applicaiton (eIND). CVVH was initiated after the development of acute renal failure, with blood samples collected to determine peramivir concentrations.
DISCUSSION:
Peramivir, an intravenous investigational neuraminidase inhibitor with activity against influenza viruses, has limited data for dosing in the setting of CVVH. A single patient received 600 mg of peramivir intravenously and had blood and ultrafiltrate concentrations measured serially. A sieving coefficient of approximately 0.9 was identified.
CONCLUSIONS:
Peramivir is well cleared by CVVH, and drug exposure is potentially predictable based on flow rates. Further study is necessary.
PMID:
22116989
[PubMed - as supplied by publisher]
Pharmacokinetic Assessment of Peramivir in a Hospitalized Adult Undergoing Continuous Venovenous Hemofiltration (December).
Scheetz MH, Griffith MM, Ghossein C, Hollister AS, Ison MG.
Source
< Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL.
Abstract
OBJECTIVE:
To report a sieving coefficient for peramivir in a patient receiving continuous venovenous hemofiltration (CVVH).
CASE SUMMARY:
An 18-year-old male presented with chills, myalgias, and dyspnea and was hospitalized. Nasal secretions were positive for influenza by rapid antigen test at an outside facility and oseltamivir was commenced. Oral absorption was predicted to be unreliable, and intravenous peramivir was accessed as an emergency investigational new drug applicaiton (eIND). CVVH was initiated after the development of acute renal failure, with blood samples collected to determine peramivir concentrations.
DISCUSSION:
Peramivir, an intravenous investigational neuraminidase inhibitor with activity against influenza viruses, has limited data for dosing in the setting of CVVH. A single patient received 600 mg of peramivir intravenously and had blood and ultrafiltrate concentrations measured serially. A sieving coefficient of approximately 0.9 was identified.
CONCLUSIONS:
Peramivir is well cleared by CVVH, and drug exposure is potentially predictable based on flow rates. Further study is necessary.
PMID:
22116989
[PubMed - as supplied by publisher]
